Latest news
Infographic: Efficacy and safety of high-dose intravitreal aflibercept 8 mg in patients with diabetic macular oedema: week 96 results from the phase 2/3 PHOTON trial - NatureNature · Fri, 07 Aug 2026 15:26:52 GMTCarl D. Regillo, MD, FASRS: Does sustained delivery outperform intermittent injections? - Ophthalmology Times EuropeOphthalmology Times Europe · Thu, 06 Aug 2026 16:07:14 GMTHow AI can help shape future clinical trials - Ophthalmology Times EuropeOphthalmology Times Europe · Wed, 05 Aug 2026 16:06:52 GMTQUASAR 64-week results: aflibercept 8 mg in macular edema following RVO—Jordana G. Fein, MD, MS - Ophthalmology Times EuropeOphthalmology Times Europe · Tue, 04 Aug 2026 16:01:45 GMTAXPAXLI Shows 72% Reduction in Injection Burden vs Aflibercept in Wet AMD - The Clinical Trial VanguardThe Clinical Trial Vanguard · Tue, 04 Aug 2026 06:43:26 GMTYesafili, an Eylea biosimilar, launches with a price of $1,445 - Managed Healthcare ExecutiveManaged Healthcare Executive · Mon, 03 Aug 2026 18:46:35 GMTBiocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg - Business WireBusiness Wire · Mon, 03 Aug 2026 11:05:00 GMTASRS 2026: Aflibercept 8 mg holds vision gains with up to 3 fewer injections in macular edema following RVO - Ophthalmology Times EuropeOphthalmology Times Europe · Fri, 31 Jul 2026 14:04:16 GMT